Document is current
Any future updates will be listed below
-
Authors
Nguyen, David N. http://orcid.org/0000-0001-6808-2717
Roth, Theodore L.
Li, P. Jonathan http://orcid.org/0000-0002-5204-6401
Chen, Peixin Amy
Apathy, Ryan
Mamedov, Murad R. http://orcid.org/0000-0002-1543-3330
Vo, Linda T.
Tobin, Victoria R.
Goodman, Daniel
Shifrut, Eric http://orcid.org/0000-0001-6827-0128
Bluestone, Jeffrey A. http://orcid.org/0000-0001-8793-7848
Puck, Jennifer M.
Szoka, Francis C. http://orcid.org/0000-0002-6236-0621
Marson, Alexander http://orcid.org/0000-0002-2734-5776
-
Funding
Funding for this research was provided by:
Division of Loan Repayment (L40 AI140341)
(P50GM082250, R01DK1199979, T32A1007641, DP3DK111914-01)
National Institutes of Health (T32 DK007418, T32GM007618)
National Institute of Diabetes and Digestive and Kidney Diseases (F30DK120213)
(P50GM082250, R01DK1199979, T32A1007641, DP3DK111914-01)
Jeffrey Modell Foundation
National Multiple Sclerosis Society (CA 1074-A-21)
Burroughs Wellcome Fund
CIS CSL Behring Fellowship Award
gifts from Jake Aronov and Barbara Bakar; American Endowment Foundation
-
License Information
Text and Data Mining valid from 2019-12-09
Version of Record valid from 2019-12-09
-
More Information
Article History
Received: 16 April 2019
Accepted: 25 October 2019
First Online: 9 December 2019
Competing interests
: A.M. is a co-founder of Spotlight Therapeutics. T.L.R. and A.M. are co-founders of ArsenalBio. J.A.B. is a founder of Sonoma Biotherapeutics. A.M. serves on the scientific advisory board of PACT Pharma, is an advisor to Trizell, and was a former advisor to Juno Therapeutics. The Marson laboratory has received sponsored research support from Juno Therapeutics, Epinomics, and Sanofi, as well as a gift from Gilead. Patents have been filed based on the findings described here. All other authors have no competing interests.
